# A Biomarker Study in Men With Localized Prostate Cancer Treated With Aglatimagene Besadenovec

Source: https://onco.cc/trials/nct07332000/  
OnCo record `nct07332000` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of Aglatimagene besadenovec in prostate cancer, run by Candel Therapeutics, Inc., now recruiting.

## Summary

A Biomarker Study in Men With Localized Prostate Cancer Treated With Aglatimagene Besadenovec is a phase 2 interventional study registered as NCT07332000 by Candel Therapeutics, Inc., with 45 participants planned, started 2025-10-30 and due to reach its primary completion in 2027-02. Interventions recorded: aglatimagene besadenovec + valacyclovir, External Beam Radiation Therapy (EBRT). Conditions listed: Prostate Cancer Patients Treated by Radiotherapy, Prostate Cancer (Adenocarcinoma). No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT07332000
- Phase: 2
- Setting: A Biomarker Study in Men With Localized, Favorable, Intermediate-risk Prostate Cancer Treated With Aglatimagene Besadenovec
- Sponsor: Candel Therapeutics, Inc.
- Enrolled: 45

## Sources

- ClinicalTrials.gov NCT07332000: https://clinicaltrials.gov/study/NCT07332000

## Connected records

- cancers: [Prostate cancer](https://onco.cc/cancers/prostate/)
- drugs: [Aglatimagene besadenovec](https://onco.cc/drugs/aglatimagene-besadenovec/)
- companies: [Candel Therapeutics](https://onco.cc/companies/candel-therapeutics/)

---
JSON: https://onco.cc/api/v1/entities/nct07332000.json